AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin.
Gemtuzumab ozogamicin (GO), an immunoconjugate between an anti-CD33 antibody and a calicheamicin-γ(1) derivative, induces remissions and improves survival in a subset of patients with acute myeloid leukemia (AML). As the mechanisms underlying GO and calicheamicin-γ(1) resistance are incompletely und...
Saved in:
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | article |
Language: | EN |
Published: |
Public Library of Science (PLoS)
2013
|
Subjects: | |
Online Access: | https://doaj.org/article/cdee93bca07145d3b4ee0e020e486f40 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|